Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health receives Medicare coverage for Guardant360 Response™ to monitor cancer patient response to immunotherapy

Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida.

Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting

Guardant Health (GH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Guardant Health (GH) Looks Ripe for Bottom Fishing

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to evaluate patient compliance with a blood-based test for colorectal cancer (CRC) screening.

Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield™, Guardant Health's blood test to screen for colorectal cancer (CRC).

Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test

The average of price targets set by Wall Street analysts indicates a potential upside of 75.5% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Guardant Health (GH)? Wall Street Analysts Think 75.47%

COMPASS Pathways

Unprofitable biopharma businesses took a beating in the bear market. Guardant Health has a new plan to slash its expenses as it grows.

2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world's leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands.

Musa Tariq Joins Guardant Health Board of Directors

Guardant Health, Inc. (NASDAQ:GH ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Alex Kleban – Vice President-Investor Relations Helmy Eltoukhy – Chairman and Co-Chief Executive Officer AmirAli Talasaz – Co-Chief Executive Officer Mike Bell – Chief Financial Officer Conference Call Participants Dan Arias – Stifel Max Masucci – Cowen Tejas Savant – Morgan Stanley Derik De Bruin – Bank of America Jack Meehan – Nephron Julia Qin – JPMorgan Puneet Souda – SVB Securities Matt Sykes – Goldman Sachs Dan Leonard – Credit Suisse Patrick Donnelly – Citi Operator Thank you for standing by, and welcome to the Guardant Health Fourth Quarter and Full Year 2022 Financial Results Call. My name is Sam, and I will be your moderator for today's call.

Guardant Health, Inc. (GH) Q4 2022 Earnings Call Transcript

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights Revenue of $126.9 million for the fourth quarter of 2022, an increase of 17% over the fourth quarter of 2021.

Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Citi 2023 Healthcare Services, MedTech, Tools & HCIT Conference in New York City, NY Fireside Chat on Wednesday, March 1st at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time Cowen 43rd Annual Health Care Conference in Boston, MA Fireside Chat on Wednesday, March 8th at 10:30 a.m.

Guardant Health to Participate in Upcoming March Investor Conferences

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the initiation of a new study to examine patient preference for Shield, Guardant Health's blood test to screen for colorectal cancer (CRC), and if having the option of a blood test improves patient adherence to screening. The study will be conducted by the Center for Asian Health Equity – University of Chicago Medicine (CAHE-UCM).

Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer

Despite recent data hiccups for Guardant Health, Inc., you can expect much more upsides to this stock. The flagship Guardant360 recently gained FDA approval as a companion diagnostic for the breast-cancer drug, Orsedu.

Guardant Health: More Catalysts To Power Leaping Growth

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that UnitedHealthcare (UHC) now covers the Guardant360® CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA-approved companion diagnostic indications. The test is used by oncologists as a companion diagnostic to assess if patients are eligible for a targeted therapy for advanced or metastatic breast or non-small cell lung cancer (NSCLC).

Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer

PALO ALTO, Calif. & NEW YORK--( BUSINESS WIRE )--Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and AnHeart Therapeutics, a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, announced today a strategic collaboration on the development, regulatory approval and commercialization of the Guardant360® CDx and Guardant360 TissueNext™ assays as companion diagnostics for taletrectinib in the United States and European Union. Taletrectinib is an investigational ROS1 inhibitor for the treatment of adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

PALO ALTO, Calif--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, issued the following statement today regarding the favorable recommendation by U.S. District Court Magistrate Judge Christopher J. Burke that nearly all claims brought by Illumina against Guardant Health in a lawsuit filed on March 17, 2022, be dismissed:

Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health's Motion to Dismiss Lawsuit Brought by Illumina

PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

PISCATAWAY, N.J.--( BUSINESS WIRE )--Sampled1 today announced that the new genomics Sampled SMART Lab in Glasgow, UK, has initiated a project with Guardant Health, Inc., a leading precision oncology company, to manage blood samples for a large-scale lung cancer screening study. The SHIELD Lung registrational study is designed to evaluate the performance of a Guardant blood-based screening test to detect lung cancer in high-risk individuals aged 50-80. Sampled has already begun receiving blood samples for the study, which is expected to enroll nearly 10,000 patients and will be conducted across approximately 100 centers in the U.S. and Europe. Sampled will manage receipt of the study's blood samples from these test sites, prepare them for analysis, and store them until they are ready to be shipped to Guardant Health's U.S. laboratories for test processing.

Sampled's Genomics Laboratory in Glasgow Launches Inaugural Project with Guardant Health

PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of Guardant GalaxyTM, a suite of advanced analytical technologies developed internally and through outside partnerships to enhance the performance and clinical utility of Guardant Health's portfolio of cancer tests and to power the next generation of biomarker and drug discovery.

Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery

Bristol-Myers

Illumina

Pfizer

Learn about some of the leading cancer stocks in the U.S stock market this year.

Investing in Cancer Stocks

PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx liquid biopsy test as a companion diagnostic to identify advanced or metastatic breast cancer patients with ESR1 mutations who may benefit from treatment with ORSERDU™ (elacestrant), a nonsteroidal selective estrogen receptor degrader to be commercialized by Stemline Therapeutics, Inc., a wholly-owned subsidiary of Menarini Group.

Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group's ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer

Harnessing the power of a simple blood test (i.e., liquid biopsy), Guardant Health has offered hope for patients through early detection of cancer. Revenues are growing robustly while there are other catalysts to catapult future growth.

Guardant Health: Positive ECLIPSE Data Signals More Upside

Affirm

AppLovin Corp

Immunovant Inc

Maxar Technologies

Madrigal Pharmaceuticals

Vaxcyte

Rogers

Rumble Inc

Prometheus Biosciences

Mid-cap stocks are proving to be an attractive investment option over the past few years.

5 Best and Worst Performing Mid-Cap Stocks in Q4 2022

LONDON & PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is partnering with The Royal Marsden NHS Foundation Trust on Part C of its “Tracking mutations in cell free DNA to predict Relapse in eArly Colorectal Cancer” (TRACC) study, which will evaluate the use of circulating tumor DNA (ctDNA) to guide chemotherapy treatment decisions after curative-intent surgery in patients with early-stage colorectal cancer (CRC). The trial is intended to determine whether patients can be spared unnecessary chemotherapy and the associated side effects if they test negative for ctDNA using the Guardant Reveal™ blood test following surgery.

Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer

News for Guardant Health Inc Stock (GH)